CytoReason vs Insitro
CytoReason vs Insitro, compared side by side on 19 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and Insitro on 62/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 62/100
- headcount growth: +13.7% against +10.9%
Insitro
- agent readiness: 40/100 against 21/100
- domain rating: 64/100 against 40/100
- headcount: 255 against 116
- funding raised: $243M against $128M
- LinkedIn following: 42,173 against 12,830
At a glance
| Measure | CytoReason | Insitro |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | Data-driven drug discovery and development company using machine learning and high-throughput biology. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Drug Discovery, Drug Development, DNA |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2016 | 2018 |
| Headquarters | Tel Aviv, Israel | South San Francisco, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | CytoReason | Insitro |
|---|---|---|
| Employees | 116 | 255 |
| Headcount growthLast 12 months | +13.7% | +10.9% |
| Total funding | $128M | $243M |
| Latest round | Series B | Series B |
| Valuation | Not published | $7.0B |
| LinkedIn followers | 12,830 | 42,173 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | Insitro |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 62/100 |
| Traction | 60/100 | 60/100 |
| Team | 70/100 | 50/100 |
| Community | Not published | 8/100 |
| Search visibility | 30/100 | 62/100 |
| Quality | 78/100 | 65/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 64/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | Insitro |
|---|---|---|
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Segment | Not detected |
CytoReason vs Insitro: common questions
Which is better, CytoReason or Insitro?
On our 0-100 score CytoReason rates higher (68/100 against 62/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 19 data points above: read the rows that match what you are buying for.
How do CytoReason and Insitro compare on the numbers?
CytoReason leads on our overall score (68/100 against 62/100), headcount growth (+13.7% against +10.9%). Insitro leads on agent readiness (40/100 against 21/100), domain rating (64/100 against 40/100), headcount (255 against 116), funding raised ($243M against $128M), LinkedIn following (42,173 against 12,830).
Read the full CytoReason review and pricing or the Insitro review and pricing. You can also browse other CytoReason alternatives we track.